1. Home
  2. SLN vs BYND Comparison

SLN vs BYND Comparison

Compare SLN & BYND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$4.83

Market Cap

318.4M

Sector

Health Care

ML Signal

HOLD

Logo Beyond Meat Inc.

BYND

Beyond Meat Inc.

HOLD

Current Price

$0.71

Market Cap

346.2M

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLN
BYND
Founded
1994
2009
Country
US
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Packaged Foods
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
318.4M
346.2M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
SLN
BYND
Price
$4.83
$0.71
Analyst Decision
Buy
Sell
Analyst Count
6
7
Target Price
$39.67
$1.70
AVG Volume (30 Days)
203.2K
28.2M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
53.80
EPS
N/A
N/A
Revenue
N/A
$326,452,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.97
$0.50
52 Week High
$7.78
$7.69

Technical Indicators

Market Signals
Indicator
SLN
BYND
Relative Strength Index (RSI) 47.85 37.85
Support Level $4.38 $0.68
Resistance Level $4.97 $0.74
Average True Range (ATR) 0.40 0.05
MACD 0.06 0.00
Stochastic Oscillator 79.20 25.45

Price Performance

Historical Comparison
SLN
BYND

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About BYND Beyond Meat Inc.

Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.

Share on Social Networks: